A decision made by the U.S. Court of Appeals for the Federal Circuit delivered a blow to Biogen Inc., denying a second look into the patent dispute filed against Mylan Pharmaceuticals Inc.
The U.S. Supreme Court on June 21 declined to hear AbbVie Inc.’s challenge to a lower court’s decision that the company violated federal antitrust law by pursuing a “sham” patent complaint against rival Perrigo Co. over AbbVie’s blockbuster testosterone replacement drug AndroGel.
The U.S. Supreme Court on June 1 declined to hear Johnson & Johnson’s bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company’s baby powder and other talc products.
In a long-running court battle over PCSK9 antibodies, Amgen lost the company’s bid to uphold patent claims for the cholesterol drug Repatha against rival drug Praluent, developed by Sanofi and Regeneron.
U.S. Supreme Court justices signaled they are unlikely to strike down the Obamacare healthcare law in a legal challenge brought by Texas and 17 other Republican-governed states and joined by President Donald Trump’s administration.
Shares of Moderna Inc. fell nearly 10% after the company lost a bid to invalidate a U.S. patent owned by Arbutus Biopharma that poses a potential obstacle to Moderna’s efforts to develop next-generation vaccines, including a coronavirus vaccine.
A federal appeals court revived nationwide litigation accusing Roche Holding AG’s Genentech unit of failing to ensure that vials of the comapny’s Herceptin breast cancer drug contained the labeled amount of the active ingredient, and that the labels misstated the drug’s concentration and volume.
A U.S. appeals court invalidated Acorda Therapeutics Inc. patents covering the multiple sclerosis drug Ampyra, opening the door to generic competition for the company’s flagship product.
A U.S. appeals court ruled invalid patents owned by Jazz Pharmaceuticals covering the company’ narcolepsy drug Xyrem, opening the door for Amneal Pharmaceuticals to launch a generic version of the medicine.
A U.S. appeals court affirmed a ruling that Merck & Co. dishonestly obtained patent rights and was not entitled to collect a $200 million infringement verdict that the company won against Gilead Sciences.